loading
Schlusskurs vom Vortag:
$13.09
Offen:
$13.14
24-Stunden-Volumen:
383.20K
Relative Volume:
0.19
Marktkapitalisierung:
$735.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-5.3264
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
-0.46%
1M Leistung:
+2.30%
6M Leistung:
+124.96%
1J Leistung:
+43.70%
1-Tages-Spanne:
Value
$12.85
$13.14
1-Wochen-Bereich:
Value
$12.85
$13.14
52-Wochen-Spanne:
Value
$3.555
$13.29

Astria Therapeutics Inc Stock (ATXS) Company Profile

Name
Firmenname
Astria Therapeutics Inc
Name
Telefon
617-349-1971
Name
Adresse
22 BOSTON WHARF ROAD, BOSTON
Name
Mitarbeiter
78
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-11
Name
Neueste SEC-Einreichungen
Name
ATXS's Discussions on Twitter

Vergleichen Sie ATXS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATXS
Astria Therapeutics Inc
12.89 747.24M 0 -72.89M -68.47M -2.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.13 115.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
776.31 81.12B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
400.17 52.54B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
839.99 51.78B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
177.12 37.12B 447.02M -1.18B -906.14M -6.1812

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-11-12 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-09-17 Bestätigt H.C. Wainwright Buy
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2025-01-31 Eingeleitet JMP Securities Mkt Outperform
2024-07-29 Eingeleitet TD Cowen Buy
2023-03-28 Eingeleitet Evercore ISI Outperform
Alle ansehen

Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten

pulisher
Jan 01, 2026

Patterns Watch: Is Astria Therapeutics Inc stock gaining market shareMarket Performance Summary & Capital Efficiency Focused Strategies - moha.gov.vn

Jan 01, 2026
pulisher
Dec 29, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Hold” by Brokerages - Defense World

Dec 29, 2025
pulisher
Dec 29, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Dec 29, 2025
pulisher
Dec 25, 2025

Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward - MSN

Dec 25, 2025
pulisher
Dec 25, 2025

Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment - MSN

Dec 25, 2025
pulisher
Dec 24, 2025

(ATXS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Dec 24, 2025
pulisher
Dec 23, 2025

Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com

Dec 23, 2025
pulisher
Dec 23, 2025

Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks

Dec 23, 2025
pulisher
Dec 23, 2025

Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets

Dec 23, 2025
pulisher
Dec 20, 2025

Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.

Dec 20, 2025
pulisher
Dec 19, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve

Dec 19, 2025
pulisher
Dec 19, 2025

Why Astria Therapeutics Inc. stock could outperform in 2025Weekly Market Outlook & High Win Rate Trade Alerts - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

Why Astria Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Reactions & Accurate Entry/Exit Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR - Sahm

Dec 19, 2025
pulisher
Dec 17, 2025

Astria Therapeutics Earnings Notes - Trefis

Dec 17, 2025
pulisher
Dec 14, 2025

Astria Therapeutics (ATXS) price target decreased by 17.94% to 21.62 - MSN

Dec 14, 2025
pulisher
Dec 13, 2025

Technical Reactions to ATXS Trends in Macro Strategies - Stock Traders Daily

Dec 13, 2025
pulisher
Dec 12, 2025

FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters

Dec 12, 2025
pulisher
Dec 11, 2025

BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com UK

Dec 11, 2025
pulisher
Dec 11, 2025

BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com

Dec 11, 2025
pulisher
Dec 10, 2025

Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co. - MarketBeat

Dec 10, 2025
pulisher
Dec 07, 2025

Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS - MarketBeat

Dec 07, 2025
pulisher
Dec 06, 2025

Affinity Asset Advisors LLC Purchases Shares of 300,000 Astria Therapeutics, Inc. $ATXS - MarketBeat

Dec 06, 2025
pulisher
Dec 04, 2025

Will Astria Therapeutics Inc. stock gain from government policies2025 Market Overview & Verified Swing Trading Watchlists - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Astria Therapeutics (NASDAQ:ATXS) Sees Large Volume IncreaseWhat's Next? - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts - MarketBeat

Dec 04, 2025
pulisher
Dec 03, 2025

BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade

Dec 03, 2025
pulisher
Dec 03, 2025

Astria Therapeutics (NASDAQ:ATXS) Sets New 1-Year HighWhat's Next? - MarketBeat

Dec 03, 2025
pulisher
Dec 03, 2025

Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus

Dec 03, 2025
pulisher
Dec 03, 2025

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times

Dec 03, 2025
pulisher
Dec 03, 2025

BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative

Dec 03, 2025
pulisher
Dec 03, 2025

BioCryst receives antitrust clearance for Astria acquisition - Investing.com

Dec 03, 2025
pulisher
Dec 03, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-TCBX, RNA, ATXS, and FSUN - The Malaysian Reserve

Dec 03, 2025
pulisher
Dec 02, 2025

Trading the Move, Not the Narrative: (ATXS) Edition - news.stocktradersdaily.com

Dec 02, 2025
pulisher
Dec 01, 2025

Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights - Sahm

Dec 01, 2025
pulisher
Nov 30, 2025

Astria Therapeutics: Updating Target Price, BioCryst Deal Expected To Go Through, Hold - Seeking Alpha

Nov 30, 2025
pulisher
Nov 22, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN - The Malaysian Reserve

Nov 22, 2025
pulisher
Nov 22, 2025

Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire

Nov 22, 2025
pulisher
Nov 21, 2025

(ATXS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com

Nov 21, 2025
pulisher
Nov 20, 2025

Will Astria Therapeutics Inc. stock split again soonJuly 2025 Summary & High Yield Equity Trading Tips - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

How Astria Therapeutics Inc. stock performs in interest rate cycles2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Will Astria Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Review & Weekly High Potential Alerts - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Can Astria Therapeutics Inc. stock deliver surprise earnings beatWeekly Stock Analysis & Fast Momentum Stock Entry Tips - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Can Astria Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Return Summary & Detailed Earnings Play Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Combining price and volume data for Astria Therapeutics Inc.2025 Support & Resistance & Long-Term Safe Return Strategies - newser.com

Nov 19, 2025

Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.86
price up icon 0.57%
$31.82
price up icon 3.31%
$101.42
price up icon 2.68%
$96.69
price up icon 1.57%
biotechnology ONC
$311.02
price up icon 2.37%
$177.12
price up icon 1.77%
Kapitalisierung:     |  Volumen (24h):